PMGC Holdings Inc. Files S-1 for IPO

Ticker: ELAB · Form: S-1 · Filed: Feb 12, 2025 · CIK: 1840563

Sentiment: neutral

Topics: ipo, registration-statement, pharmaceuticals

TL;DR

PMGC Holdings Inc. (fka Elevai Labs) just filed its S-1 for an IPO. Get ready.

AI Summary

PMGC Holdings Inc. filed an S-1 registration statement on February 11, 2025, for its initial public offering. The company, formerly known as Elevai Labs Inc. and Reactive Medical Labs Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector. Its principal executive offices are located at 120 Newport Center Drive, Suite 250, Newport Beach, CA 92660.

Why It Matters

This S-1 filing indicates PMGC Holdings Inc. is preparing to become a publicly traded company, which could offer new investment opportunities and impact the pharmaceutical preparations market.

Risk Assessment

Risk Level: medium — As an S-1 filing, it represents a company seeking to go public, which inherently carries risks associated with market volatility and the company's unproven public performance.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of PMGC Holdings Inc.?

PMGC Holdings Inc. operates in the Pharmaceutical Preparations sector, with SIC code 2834.

When was the S-1 filing submitted?

The S-1 registration statement was filed with the U.S. Securities and Exchange Commission on February 11, 2025.

What were PMGC Holdings Inc.'s previous names?

The company was formerly known as Elevai Labs Inc. (name change effective 20211207) and Reactive Medical Labs Inc. (name change effective 20210114).

Where are PMGC Holdings Inc.'s principal executive offices located?

The principal executive offices are located at 120 Newport Center Drive, Suite 250, Newport Beach, CA 92660.

What is the SEC file number for this registration statement?

The SEC file number for this registration statement is 333-284851.

Filing Stats: 4,354 words · 17 min read · ~15 pages · Grade level 13.6 · Accepted 2025-02-12 06:19:01

Key Financial Figures

Filing Documents

RISK FACTORS

RISK FACTORS 8 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 36

USE OF PROCEEDS

USE OF PROCEEDS 37 DETERMINATION OF OFFERING PRICE 37 DIVIDEND POLICY 37 MARKET INFORMATION 37 PMGC HOLDINGS INC. AND SUBSIDIARIES 38

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 44

BUSINESS

BUSINESS 56 MANAGEMENT 75

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 80 PRINCIPAL STOCKHOLDERS 87 SELLING SHAREHOLDERS 89 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 84

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 91 PLAN OF DISTRIBUTION 95 EXPERTS 96 LEGAL MATTERS 96 WHERE YOU CAN FIND MORE INFORMATION 96 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on the information contained in this prospectus or any prospectus supplement or amendment. Neither we, nor the placement agent, have authorized any other person to provide you with information that is different from, or adds to, that contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor the placement agent take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should assume that the information contained in this prospectus or any free writing prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. We are not making an offer of any securities in any jurisdiction in which such offer is unlawful. No action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this public offering and the distribution of this prospectus applicable to that jurisdiction. i ABOUT THIS PROSPECTUS Throughout this prospectus, unless otherwise designated or the context suggests otherwise, all references to the "Company," "PMGC," the "registrant," "we," "our" or "us" in this prospectus mean PMGC Holdings Inc. and its wholly owned subsidiaries, PMGC Capital LLC, Northstrive Biosciences Inc. and PMGC Research Inc.; "year" or "fiscal year" means

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing